Rana Al-Hallaq


Dr. Rana Al-Hallaq (PhD) is Executive Director, Worldwide Business Development and Partner at Pfizer Ventures. She is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. She is currently on the Board of Autifony Therapeutics, Biograph55, Nucleome Therapeutics, ReCode Therapeutics, RefleXion Medical, and Vivet Therapeutics as well as managing investments in Jnana Therapeutics, the Dementia Discovery Fund, and the Wellington Access Ventures Fund.

Prior to her current role, Dr. Al-Hallaq was a Transactionalist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. She joined Pfizer in 2015 as an Early Candidate Clinical Lead where she advised early clinical programs in CNS to ensure alignment with business strategies. Prior to joining Pfizer, she held roles at Allergan (formerly Actavis, formerly Forest Laboratories), first in Clinical Development Psychiatry as scientific and operational lead on Phase 2 and Phase 3 studies, and later in Business Development where she assessed and executed on a number of acquisitions and licenses across therapeutic areas. She began her training as a research fellow at the National Institutes of Health.

Dr. Al-Hallaq received her BA in Biology from Hamilton College and holds a PhD in Neuroscience from Georgetown University Medical Center.